Inflammatix Ships TriVerity™ Test Cartridges and Myrna™ Instruments to the U.S. Military

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field

Inflammatix receives an initial $1.2 million to cover the first phase of system evaluation, with future phase options worth up to $20.8 million

SUNNYVALE, Calif., March 25, 2025 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today announced the shipment of TriVerity™ cartridges and Myrna™ instruments to the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to facilitate the differentiation of bacterial infections, viral infections, and non-infectious illness. In the first phase of its agreement with Inflammatix, the JPEO-CBRND, which manages the acquisition, fielding and sustainment of chemical, biological, radiological, and nuclear (CBRN) defense capabilities to the joint force, will assess the viability of TriVerity cartridges and Myrna™ instruments for field use. The initial shipment, for which Inflammatix is to receive more than $1.2 million, is part of a JPEO-CBRND contract worth up to $20.8 million if all options are exercised.

TriVerity, Inflammatix's flagship product, is a rapid blood test that measures the expression levels of 29 genes involved in the immune response associated with acute infection status and illness severity. The device, which was cleared for clinical use by the U.S. Food and Drug Administration (FDA) on January 10, 2025, is designed to facilitate management of patients presenting with suspected acute infection or sepsis. As part of the first phase of the contract, the JPEO-CBRND will conduct cybersecurity analyses of TriVerity and evaluate the system's suitability in a deployed military setting where personnel may be confronted with biothreat and endemic infectious diseases. The remainder of the contract grants the JPEO-CBRND the option to ruggedize and/or improve the Myrna instrument and enhance the test system for use in a field-forward setting.

"We are pleased that the JPEO-CBRND has chosen to evaluate our TriVerity Test System, including TriVerity cartridges and the Myrna instrument, for military use," said Dr. Timothy Sweeney, CEO and co-founder of Inflammatix. "TriVerity's ability to rapidly rule in and rule out bacterial infection, viral infection and illness severity has the potential to streamline triage for our Armed Forces in forward environments. We are confident that this robust test system, which we have built for routine clinical use, can be modified and optimized for use in military settings."

The JPEO-CBRND contract comes at a time of increasing risk of acute infection and sepsis in the U.S. military. Data suggest that soldiers in combat zones are at elevated risk of respiratory infections, with an incidence nearly three times as great as that in the adult civilian population; more than 40% of soldiers' respiratory illnesses are attributed to unknown causative agents.¹ In an analysis of sepsis hospitalization data of active military personnel from January 1, 2011, to December 31, 2020, researchers reported an overall incidence of 39.8 hospitalizations per 100,000 person-years. The annual incidence increased 64% from 2011 through 2019, then dropped in 2020, during the COVID-19 pandemic.² These trends highlight the need for a portable, well-built diagnostic test that can rapidly and reliably detect the presence and assess the severity of infection under battlefield conditions.

Disclaimer: The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government and reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the U.S. government and shall not be used for advertising or product endorsement purposes.

About the TriVerity™ Test System

The TriVerity™ Test System ("TriVerity"), Inflammatix's flagship in vitro diagnostic (IVD) test, includes the TriVerity cartridge and the Myrna™ instrument. TriVerity incorporates a panel of 29 patient messenger RNAs (mRNAs) to rapidly "read" the body's immune response to infection using machine learning-derived algorithms. TriVerity shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments. TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition.

About Inflammatix

Inflammatix, Inc., based in Sunnyvale, California, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient's immune response. Our innovative diagnostics aim to improve patient care and tackle significant public health challenges. Designed for our advanced sample-to-answer isothermal instrument platform, our tests bring the power of precision medicine to the point of care. The company's funders include Khosla Ventures, Northpond Ventures, Think.Health Ventures, D1 Capital, Iberis Capital, and Vesalius BioCapital, and the Stanford-StartX Fund. For more information, please visit www.inflammatix.com and follow the company on LinkedIn and X (formerly Twitter) at @Inflammatix_Inc).

Inflammatix product development has been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; and the Biomedical Advanced Research and Development Authority, under contract numbers 75A50119C00034, 75A50119C00044, and 75A50122C00069.

TriVerity, Myrna, and Inflammatix are trademarks of Inflammatix, Inc. in the U.S. and other countries and regions.

References

1. Korzeniewski K, Nitsch-Osuch A, Konior M, Lass A. Respiratory tract infections in the military environment. Respir Physiol Neurobiol. 2014;209:76-80.
2. Snitchler CL, Patel DM, Stahlman SL, Chauhan AV, Wells NY, Mcquistan AA. Sepsis hospitalizations among active component service members, U.S. Armed Forces, 2011-2020. MSMR. 2021;28(11):2-8.

SOURCE Inflammatix